secwatch.observer — SEC 8-K summary
======================================

Issuer:     Polaryx Therapeutics, Inc. (PLYX)
CIK:        0002075320
Form:       8-K
Filed at:   2026-07-21T20:30:46+00:00
Accession:  0001213900-26-080041
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediately
---------------------------------------------------------------------

- CMO Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately.
- Company states resignation will not affect clinical timelines, regulatory plans, or development strategy.
- Search for successor commenced; existing leadership team will assume CMO responsibilities in interim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/0001213900-26-080041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/ea0298434-8k_polaryx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-080041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer